11β-Hydroxysteroid Dehydrogenase Type 1 As a Potential Treatment Target in Cardiovascular Diseases

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Oct 27

PMID 36294507

Authors

Daria Kupczyk

Renata Studzinska

Renata Kolodziejska

Szymon Baumgart

Martyna Modrzejewska

Alina Wozniak

Affiliations

Soon will be listed here.

Abstract

Glucocorticoids (GCs) belong to the group of steroid hormones. Their representative in humans is cortisol. GCs are involved in most physiological processes of the body and play a significant role in important biological processes, including reproduction, growth, immune responses, metabolism, maintenance of water and electrolyte balance, functioning of the central nervous system and the cardiovascular system. The availability of cortisol to the glucocorticoid receptor is locally controlled by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Evidence of changes in intracellular GC metabolism in the pathogenesis of obesity, metabolic syndrome (MetS) and cardiovascular complications highlights the role of selective 11β-HSD1 inhibition in the pharmacotherapy of these diseases. This paper discusses the role of 11β-HSD1 in MetS and its cardiovascular complications and the importance of selective inhibition of 11β-HSD1.

Citing Articles

Lipophilic Studies and In Silico ADME Profiling of Biologically Active 2-Aminothiazol-4(5)-one Derivatives.

Redka M, Baumgart S, Kupczyk D, Kosmalski T, Studzinska R Int J Mol Sci. 2023; 24(15).

PMID: 37569606 PMC: 10418735. DOI: 10.3390/ijms241512230.

Synthesis of Novel 2-(Cyclopentylamino)thiazol-4(5)-one Derivatives with Potential Anticancer, Antioxidant, and 11β-HSD Inhibitory Activities.

Baumgart S, Kupczyk D, Archala A, Koszla O, Solek P, Plazinski W Int J Mol Sci. 2023; 24(8).

PMID: 37108415 PMC: 10139140. DOI: 10.3390/ijms24087252.

References

Sapolsky R, Romero L, Munck A . How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000; 21(1):55-89. DOI: 10.1210/edrv.21.1.0389. View

Krozowski Z, Li K, Koyama K, Smith R, Obeyesekere V, Sasano H . The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999; 69(1-6):391-401. DOI: 10.1016/s0960-0760(99)00074-6. View

Mune T, White P . Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension. 1996; 27(6):1193-9. DOI: 10.1161/01.hyp.27.6.1193. View

Palermo M, Quinkler M, Stewart P . Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metabol. 2005; 48(5):687-96. DOI: 10.1590/s0004-27302004000500015. View

Goedecke J, Wake D, Levitt N, Lambert E, Collins M, Morton N . Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf). 2006; 65(1):81-7. DOI: 10.1111/j.1365-2265.2006.02552.x. View

Paterson J, Seckl J, Mullins J . Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol. 2005; 289(3):R642-52. DOI: 10.1152/ajpregu.00017.2005. View

Berg A, Scherer P . Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96(9):939-49. DOI: 10.1161/01.RES.0000163635.62927.34. View

Staab C, Maser E . 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol. 2010; 119(1-2):56-72. DOI: 10.1016/j.jsbmb.2009.12.013. View

Nicolaides N, Galata Z, Kino T, Chrousos G, Charmandari E . The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2009; 75(1):1-12. PMC: 2813911. DOI: 10.1016/j.steroids.2009.09.002. View

10.

Sjostrand M, Jansson P, Palming J, de Schoolmeester J, Gill D, Rees A . Repeated measurements of 11β-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects--no change following a mixed meal. Horm Metab Res. 2010; 42(11):798-802. DOI: 10.1055/s-0030-1254134. View

11.

Seckl J . 11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?. Front Neuroendocrinol. 1997; 18(1):49-99. DOI: 10.1006/frne.1996.0143. View

12.

Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G . AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 2008; 22(6):1672-83. DOI: 10.1096/fj.07-094144. View

13.

Hardy R, Fenton C, Croft A, Naylor A, Begum R, Desanti G . 11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis. J Autoimmun. 2018; 92:104-113. PMC: 6066611. DOI: 10.1016/j.jaut.2018.05.010. View

14.

Kwon S, Kang S, Lee J, Bok J, Kim C, Rhee S . Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group. Bioorg Med Chem Lett. 2010; 21(1):435-9. DOI: 10.1016/j.bmcl.2010.10.123. View

15.

Hong S, Nam K, Shin Y, Kim K, Ahn S . Discovery of 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Bioorg Med Chem Lett. 2015; 25(17):3501-6. DOI: 10.1016/j.bmcl.2015.06.099. View

16.

Wake D, Walker B . Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity. Endocrine. 2006; 29(1):101-8. DOI: 10.1385/ENDO:29:1:101. View

17.

Stimson R, Andrew R, McAvoy N, Tripathi D, Hayes P, Walker B . Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes. 2011; 60(3):720-5. PMC: 3046832. DOI: 10.2337/db10-0726. View

18.

Webster S, Ward P, Binnie M, Craigie E, McConnell K, Sooy K . Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007; 17(10):2838-43. DOI: 10.1016/j.bmcl.2007.02.057. View

19.

Basciano H, Federico L, Adeli K . Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond). 2005; 2(1):5. PMC: 552336. DOI: 10.1186/1743-7075-2-5. View

20.

Yuan C, St Jean Jr D, Liu Q, Cai L, Li A, Han N . The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007; 17(22):6056-61. DOI: 10.1016/j.bmcl.2007.09.070. View